![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Harry Erba, MD, PhD
Leukemia Specialist
Specialities: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia
Spoken languages: English
Clinical Expertise
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
About
Dr. Erba's research focus is on clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia. Specifically, he has been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy. Dr. Erba has been an active member of teams of doctors that have brought new treatments to people with AML, such as oral drugs that inactivate FLT3 and IDH.
Location
Duke University Medical Center: Ambulatory Surgery Center, 2400 Pratt St, Durham, NC 27705, USA
Get the latest thought leadership on your Myeloproliferative Neoplasm delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2024 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811